Abstract
Introduction Increases in global childhood vaccine delivery have led to decreases in morbidity from vaccine-preventable diseases. However, these improvements in vaccination have been heterogeneous, with some countries demonstrating greater levels of change and sustainability. Understanding what these high-performing countries have done differently and how their decision-making processes will support targeted improvements in childhood vaccine delivery.
Methods and analysis We studied three countries - Nepal, Senegal, Zambia - with exemplary improvements in coverage between 2000-2018 as part of the Exemplars in Global Health Program. We apply established implementation science frameworks to understand the “how” and “why” underlying improvements in vaccine delivery and coverage. Through mixed methods research we will identify drivers of catalytic change in vaccine coverage and the decision-making process supporting these interventions and activities. Methods include quantitative analysis of available datasets and in-depth interviews and focus groups with key stakeholders in the global, national, and sub-national government and non-governmental organization space, as well as community members and local health delivery system personnel.
Ethics and dissemination Working as a multinational and multidisciplinary team, and under oversight from all partner and national-level (where applicable) institutional review boards, we collect data from participants who provided informed consent. Findings are disseminated through a variety of forms, including peer-reviewed manuscripts related to country-specific case studies and vaccine system domain-specific analyses, presentations to key stakeholders in the global vaccine delivery space, and narrative dissemination on the Exemplars.Health website.
Strengths and limitations of this study
This study is led by a multidisciplinary team and grounded in several theoretical frameworks across disciplines from implementation science to behavioral theory.
We utilized a cross cutting, cross-disciplinary, approach, which assessed relevant domains across our selected exemplars countries as well as within the subjects that arise from the data, over a roughly 20-year time horizon.
We selected three countries with historically high unvaccinated populations to represent different geographies, cultures, and governments, as well as to highlight regions with historically high unvaccinated populations.
We did not study a less successful, or “non-exemplar”, counterfactual country.
The research tools identified and explored catalytic events and the implementation of external policies and development of internal policies and systems, with a focus on participants’ current experiences and perceptions of prior activities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Bill & Melinda Gates Foundation, grant number OPP1195041. Pilot and proposal development funds were provided by Gates Ventures.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Emory University Institutional Review Board (IRB); the Nepal Health Research Council in Nepal; the University of Zambia Biomedical Research Ethics Committee and the National Health Research Authority in Zambia; and the Comite de National d Ethique pour la Recherche en Sante (CNERS; National Ethical Committee for Health Research) in Senegal.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Vaccine Exemplars Research Consortium Co-Authors: Natália S. Bueno, Bonheur Dounebaine, Kimberley R. Isett, Pinar Keskinocak, B. Pablo Montagnes, Dima Nazzal, Saad Omer, Walter Orenstein, Miguel R. Robayo, Simone Rosenblum, Francisco Castillo Zunino
Note that all authors have seen and approved of this manuscript.
Data Availability
Data available upon request.